Health News

NEW YORK--(BUSINESS WIRE)--RYALTRIS® nasal spray for seasonal allergic rhinitis is now available through BlinkRx. Transfer your Rx or visit blinkrx.com to learn more....

LEXINGTON, Ky.--(BUSINESS WIRE)--Valvoline Inc. (NYSE: VVV), the quick, easy, trusted leader in preventive automotive maintenance, today announced it is becoming the first Ronald McDonald House Global corporate partner dedicated solely to funding mental health initiatives. Representing a $750,000 total commitment over three years, the partnership reflects a shared dedication to strengthening families and improving health outcomes in communities across the United States. In year one, Valvoline I...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead pr...

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services markets, today announced that it will release its interim financial results for the quarter ended March 31, 2026 before markets open on Thursday, May 14, 2026. Investors and stake...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus nadofaragene firadenovec-vncg and TAR-200 in patients with non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease, at the American Urological Association Annual Meeting (AUA 20...

SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the grand opening of the ZAP-X® Gyroscopic Radiosurgery® system at Kaohsiung Show Chwan Memorial Hospital (KSCH) in Taiwan. The ceremony marked a significant milestone in advancing access to next-generation non-invasive brain neurosurgery in the region. Featuring an innovative and visually striking treatment suite, patient treatments with the ZAP-X system are e...

BOSTON--(BUSINESS WIRE)--Inlightened, the tech-enabled insights platform that connects client companies to a vetted network of healthcare professionals, today announced that Rob Ramirez has joined the company as head of strategy. Ramirez brings 30 years of experience in pharmaceutical market research, healthcare insights, and commercial strategy, including senior leadership roles at Pfizer, Ipsos Healthcare, Schlesinger Group (now Trivoca Health), and, most recently, Manifest Health. Ramirez is...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating pegsebrenatide (NLY01), Neuraly’s long-acting GLP1 receptor agonist, for the potential treatment of patients with multiple sclerosis (MS). Multiple sclerosis is a chronic and progressive autoimmune disease of the central nervous system (CNS) affecting more than 2.8 mil...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the EL...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline data fro...